SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today reported financial results for the three-month period ended March 31, 2015. Company Highlights Successfully implanted 19 Argus® II systems in the first quarter of 2015, the highest number for any quarter to date; Net revenue increased 159% to $1.7 millio
LONDON–(BUSINESS WIRE)–Technavio has published a new report on the global capsule endoscope market, which is expected to grow at a CAGR of 11% from 2015-2019.
PORTLAND, Ore.–(BUSINESS WIRE)–Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, announced today that it has entered into a multi-year agreement with global healthcare supplier Perrigo Company plc to promote the ilast® range of products for eyelid hygiene in the United States. “The ilast® brand is an integral part of our portfolio of branded products,” said Patrick Witham, President and CEO of Paragon BioTeck, Inc. “By expanding our promotional efforts to incl
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the UBS Global Healthcare Conference in New York City on Monday, May 18, 2015.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jjzjdp/north_american) has announced the addition of the “North American Ophthalmology Surgery Devices Market by Types, by End-users – Forecast to 2019” report to…
LONDON–(BUSINESS WIRE)–ISG has commenced work on a £4.5 million project to create a state-of-the-art eye hospital in London’s renowned Marylebone medical district, for high-end ophthalmic specialist Optegra. The scheme involves the conversion of two period properties in Queen Anne Street into an advanced facility for the treatment of a comprehensive range of eye conditions. Retaining the attractive Edwardian and Victorian façades of the two buildings, ISG will rationalise and unify space and
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Reports First Quarter 2015 Financial Results
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces two tech evaluation agreements with leading global pharmaceutical company to evaluate use of pSivida’s Durasert technology for ophthalmology.
SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. “FibroGen and its partners, AstraZeneca and Astellas, continue to make excellent progress in the global development of roxadustat for the treatment of anemia in patients with chronic kidney disease,” said Thomas B. Neff, chief executive officer of FibroGen. “Patient enrollment in the seven Phase 3 studies re
TOKYO–(BUSINESS WIRE)–HOYA Corporation (TOKYO: 7741) today announced financial results for the fourth quarter and full-year ended March 31, 2015. During the quarter, revenues increased by 10.6% to 127,440 million yen compared with the same period las…
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial results for the first quarter ended March 31, 2015 and provided an update on the Company’s business and product development programs.
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced the completion of patient recruitment of its first Phase 3 trial of Fovista® in combination with Lucentis® (ranibizumab).
ACTON, Mass.–(BUSINESS WIRE)–“2015 World Medical Innovation Forum” cites “Early Diagnosis and Treatment of Alzheimer’s Disease” as the top field where breakthroughs will be made
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City. “Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough c
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this year’s annual meeting of the American Association for Cancer Resea
DUBLIN–(BUSINESS WIRE)–PRESBIA TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Features Key Opinion Leaders in Ophthalmology and Optometry in Analyst and Investor Day Event on May 19
MUNICH–(BUSINESS WIRE)–Our preclinical data support the compound’s potential to protect glaucoma patients’ vision and we see other high medical need diseases that could potentially benefit from TGF-β-targeted treatment.